Cabergoline in prolactinomas

Anna B. Fierz Center for Clinical Neurosciences and Ophthalmology, Michigan State University, East Lansing, MI,

David I. Kaufman Center for Clinical Neurosciences and Ophthalmology, Michigan State University, East Lansing, MI,

Andrew G. Lee Departments of Ophthalmology, Neurology, and Neurosurgery, Baylor College of Medicine, Houston, TX and Departments of; Departments of Neurosurgery and

Eric R. Eggenberger Center for Clinical Neurosciences and Ophthalmology, Michigan State University, East Lansing, MI,

Keith E. Friend Endocrinology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA

Abstract

Cabergoline is a potent, D2-selective new dopamine agonist with a half-life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cabergoline in prolactinomas

Information for

Open access

Opportunities

Help and information

Cabergoline in prolactinomas

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature